Navigation Links
Questcor Pharmaceuticals Reports Strong Finish to 2011
Date:1/6/2012

tions: the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of nephrotic syndrome, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." Questcor is also exploring the use of Acthar to treat systemic lupus erythematosus, or SLE, for which Acthar is approved as both a maintenance therapy and to treat exacerbations. Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need. For more information about Questcor, please visit www.questcor.com.  

Note: Except for the historical information contained herein, this press release contains forward-looking statements that are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described.  All such statements have been made pursuant to the Private Securities Litigation Reform Act of 1995, as amended. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "if," "should," "forecasts," "intends," "exploring," "expects," "plans," "appears," "grows," "believes," "estimates," "predicts," "potential," "continue" or "trends" or the negative of such terms and other comparable terminology. These statements are only predictions. Actual events or results may differ materially. Factors that could cause or contribute to such differences include, but are not limited to, the following:


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Questcor Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference on November 30, 2011
2. Questcor Pharmaceuticals to Present at CLSAs 4th Annual AsiaUSA Forum on November 7, 2011
3. Questcor and Child Neurology Foundation Support the 3rd Annual Infantile Spasms (IS) Awareness Week
4. Questcor Reports Third Quarter Financial Results
5. Questcor to Report Third Quarter 2011 Earnings and Conduct Conference Call on October 25, 2011
6. Questcor Pharmaceuticals Announces Preliminary Operating Metrics for Third Quarter 2011
7. Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on September 28, 2011
8. Questcor Provides Updated New Paid Prescription Trends
9. UPDATING and ADDING: Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September
10. Questcor Pharmaceuticals to Present at the Canaccord Genuity Growth Conference on August 11, 2011
11. Questcor to Report Second Quarter 2011 Earnings and Conduct Conference Call on July 26, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... China, Dec. 24, 2014 /PRNewswire/  -- Tianyin Pharmaceutical ... pharmaceutical company that specializes in the patented biopharmaceutical, ... active pharmaceutical ingredients (API) released unaudited preliminary financial ... 2015. Fiscal Year 2015 Ended September ... $9.7 million compared with $14.7 million in 1Q14 ...
(Date:12/24/2014)... , Dec. 24, 2014  The International Trade Commission (ITC) ... (RMD) against BMC Medical. In a notice issued on December ... that ResMed,s patent on its humidifier was invalid. ... "monumental win". "We are very excited with the ITC,s decision ... that we have taken since the very beginning on the ...
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, 2014 ... a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics ... medical need and commercial potential, today announced that ... 2,050,000 shares of its common stock and Series ... common stock.  Funds under the management of QVT ...
Breaking Medicine Technology:TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4
... 25, 2011 Omthera Pharmaceuticals, Inc., a privately-held emerging ... has joined the Company as Vice President of Quality. ... Operating Officer, Drs. Ben Machielse, Mr. Maines will be ...   Mr. Maines brings to the Company ...
... 2011 GlaxoSmithKline, one of the world,s leading ... 10 winners of its GlaxoSmithKline IMPACT Awards. In ... organizations will receive $400,000 in grant funding for ... their communities. Three of the North ...
Cached Medicine Technology:Timothy J. Maines Joins Omthera Pharmaceuticals as Vice President of Quality 2GlaxoSmithKline to Grant $400,000 to Healthcare Nonprofits at Annual IMPACT Awards 2GlaxoSmithKline to Grant $400,000 to Healthcare Nonprofits at Annual IMPACT Awards 3
(Date:12/24/2014)... Mike Billings , PT, MS, CEEAA, President ... PT, MBA, GCS, Director of Professional Development to discuss ... of the Improving Medicare Post-Acute Care Transformation Act ... the Infinicast, the two leaders discuss how the IMPACT ... to standardize post-acute assessment data for quality, payment, and ...
(Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. 23, 2014 ... sex for one year will be allowed to donate blood in ... a 31-year ban on donations from men who have sex with ... intention to release a new draft guidance in early 2015 that ... The FDA is changing its policy based on data from ...
(Date:12/24/2014)... C infection does not contribute to mental decline in people ... have made it possible for people with HIV to survive ... swings and other types of mental impairment as they age, ... with other viruses -- a common problem in people with ... suspects has been the hepatitis C virus, which infects about ...
(Date:12/24/2014)... Adults who experienced childhood abuse or neglect have ... study published online Dec. 24 in the journal ... long-lasting effects, like associated medical and psychological conditions ... director of behavioral medicine at Montefiore Headache Center ... news release. "When managing patients with migraine, ...
(Date:12/24/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, ... start smoking or drinking with each additional symptom they ... new research suggests. "Our findings underscore the ... use as [these] children approach adolescence," said study author ... Group, which is part of Cincinnati Children,s Hospital. "This ...
Breaking Medicine News(10 mins):Health News:Latest Episode of Infinicast Features Infinity Rehab President Discussing IMPACT Act of 2014 and Changes for Post-Acute Therapy Providers in 2015 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 3Health News:Hepatitis C Infection Isn't Related to HIV Brain Woes: Study 2Health News:Abuse in Childhood Tied to Migraines in Adulthood 2Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 2Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 3
... to the State, While Market Leader Remains, ... Report from HealthLeaders-InterStudy, NASHVILLE, Tenn., Feb. 11 ... intelligence, reports that pay-for-,performance programs have yet to ... Health Plan Analysis, the state,s local major insurer, ...
... Senior Living Inc.,(NYSE: BKD ) (the "Company") today ... the Company,s Board of Directors,effective February 7, 2008. In ... his position as Co-CEO, and will no longer serve ... Sheriff, Brookdale,s Co-CEO,will remain as the sole Chief Executive ...
... popularity amongst,British men and women to travel to Malaysia ... at an enormous rate - leading,operator Gorgeous Getaways witnessed ... in 2007., The reasons for travelling to ... 75% less than at home), 2. Quality (accredited ...
... LONDON, February 11 Amarin Corporation plc,(NASDAQ: ... notification from The,Nasdaq Stock Market that the Company ... bid price requirement for continued listing on the ... In,the notification, Nasdaq advised that the Company has ...
... SALT LAKE CITY, Feb. 11 Two Little Hands ... the hit public television,show designed to teach babies, toddlers ... -- will debut its second season at this,year,s Toy ... (Photo: http://www.newscom.com/cgi-bin/prnh/20080211/LAM029 ), Like the ...
... loving our reefs to death? Florida biochemist says coral-killing ... synthetics harm humans, ... coral reefs,choose your sunscreen wisely, Florida biochemist Celia Ferreira, Ph.D.,advises., ... 4,000 to 6,000 tons of sunscreen that wash off swimmers every,year., ...
Cached Medicine News:Health News:Pay-For-Performance Not Getting a Red-Carpet Reception in Arizona 2Health News:Brookdale Senior Living Announces Changes in Senior Management and Board of Directors 2Health News:Surgery Holidays to Malaysia - British Women Tell Their Stories 2Health News:Amarin Regains Compliance With Nasdaq Listing Requirements 2Health News:Two Little Hands Productions, Creators of Popular Children's TV Series Signing Time, Debuts Second Season at This Year's Toy Fair 2008 2Health News:Choose Biodegradable Sunscreen to Save Coral Reefs 2
Medium clip size, 10mm...
... in 10mm and 5mm sizes. Our market-leading ... placement., ,The LIGACLIP ERCA Endoscopic Rotating ... patient use instrument designed to provide a ... The instrument delivers 20 titanium clips that ...
... utilizes turbidimetric immunoassay methodology which is a ... of 0.2-28.0 mg/dL. This assay is homogeneous, ... clinical chemistry analyzers. The Wako CRP-HS assay ... linearity, correlation, and sensitivity. Expected values are ...
... Piccolo is the first compact, broad menu ... testing in any treatment setting. Care givers ... panels with less than one minute of ... comparable in quality to larger, expensive laboratory ...
Medicine Products: